Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00774046 · ClinicalTrials.gov registry record · Phase 2
High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT00774046 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 32 participants.
The verdict
NCT00774046, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the effectiveness of a particular combination of drugs used to treat cancer.
Interventions
- DRUG Etoposide
- DRUG Mitoxantrone
- DRUG Ara-C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2002-12 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00774046
The ClinicalTrials.gov registry entry for NCT00774046 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Etoposide is the first listed.
NCT00774046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00774046 about?
NCT00774046 is a clinical study titled "High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AML". The purpose of this study is to determine the effectiveness of a particular combination of drugs used to treat cancer.
What is the current status of trial NCT00774046?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2002-12. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00774046?
The interventions under investigation include: Etoposide (DRUG), Mitoxantrone (DRUG), Ara-C (DRUG).
Who is sponsoring clinical trial NCT00774046?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.